Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma

被引：17

作者：

Dreno, Brigitte ^{[1
]}

Ascierto, Paolo A. ^{[2
]}

Atkinson, Victoria ^{[3
]}

Liszkay, Gabriella ^{[4
]}

Maio, Michele ^{[5
]}

Mandala, Mario ^{[6
]}

Demidov, Lev ^{[7
]}

Stroyakovskiy, Daniil ^{[8
]}

Thomas, Luc ^{[9
]}

de la Cruz-Merino, Luis ^{[10
]}

Dutriaux, Caroline ^{[11
]}

Garbe, Claus ^{[12
]}

Bartley, Karen ^{[13
]}

Karagiannis, Thomas ^{[13
]}

Chang, Ilsung ^{[13
]}

Rooney, Isabelle ^{[13
]}

Koralek, Daniel O. ^{[13
]}

Larkin, James ^{[14
]}

McArthur, Grant A. ^{[15
,16
,17
]}

Ribas, Antoni

机构：

[1] Nantes Univ, Dept Dermato Cancerol, F-44093 Nantes, France

[2] Fdn G Pascale, Ist Nazl Tumori, I-80131 Naples, Italy

[3] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia

[4] Natl Inst Oncol, H-1122 Budapest, Hungary

[5] Azienda Osped Univ Senese, I-53100 Siena, Italy

[6] Papa Giovanni XXIII Hosp, Dept Oncol & Haematol, I-24127 Bergamo, Italy

[7] NN Blokhin Russian Canc Res Ctr, Moscow 115478, Russia

[8] Moscow City Oncol Hosp 62, Krasnogorsk 14301, Russia

[9] Ctr Hosp Lyon Sud, Serv Dermatol, F-69495 Pierre Benite, France

[10] Hosp Univ Virgen Macarena, Seville 41009, Spain

[11] Hop St Andre, F-33075 Bordeaux, France

[12] Univ Tubingen, Dept Dermatol, D-72074 Tubingen, Germany

[13] Genentech Inc, San Francisco, CA 94080 USA

[14] Royal Marsden NHS Fdn Trust, London SW3 6JJ, England

[15] Peter MacCallum Canc Ctr, East Melbourne, Vic 3002, Australia

[16] Univ Melbourne, Parkville, Vic 3052, Australia

[17] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA

来源：

BRITISH JOURNAL OF CANCER | 2018年 / 118卷 / 06期

关键词：

vemurafenib; cobimetinib; MEK inhibitor; BRAF inhibitor; HRQOL; EORTC QLQ-C30; metastatic melanoma; DABRAFENIB; TRAMETINIB; MONOTHERAPY; PHASE-3;

D O I：

10.1038/bjc.2017.488

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAF(V600)-mutated melanoma. An analysis of health-related quality of life (HRQOL) from coBRIM is reported. Methods: Patients completing the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline and >= 1 time point thereafter constituted the analysis population. Change from baseline >= 10 points was considered clinically meaningful. Results: Mean baseline scores for all QLQ-C30 domains were similar between arms. Most on-treatment scores for QLQ-C30 domains were also comparable between arms. A transient deterioration in role function in cycle 1 day 15 (C1D15; -14.7 points) in the P+V arm and improvement in insomnia in the C+V arm at C2D15 (-12.4 points) was observed. Among patients who experienced a >= 10-point change from baseline (responders), between-group differences were greatest for insomnia (16%), social functioning (10%), fatigue (9%) and pain (7%), all favouring C+V. Diarrhoea, photosensitivity reaction, pyrexia, and rash did not meaningfully affect global health status (GHS). Serous retinopathy was associated with a transient decrease in GHS at C1D15 assessment. Conclusions: In patients with advanced/metastatic BRAFV600-mutated melanoma, treatment with C+V maintained HRQOL compared with P+V, with superior efficacy.

引用

页码：777 / 784

页数：8

共 11 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2]

Atkinson V, 2015, SOC MEL RES 2015 C 1

[3] Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study [J].

Dreno, B. ;

Ribas, A. ;

Larkin, J. ;

Ascierto, P. A. ;

Hauschild, A. ;

Thomas, L. ;

Grob, J. -J. ;

Koralek, D. O. ;

Rooney, I. ;

Hsu, J. J. ;

McKenna, E. F. ;

McArthur, G. A. .

ANNALS OF ONCOLOGY, 2017, 28 (05) :1137-1144

[4] Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study. [J].

Dreno, Brigitte ;

Ascierto, Paolo Antonio ;

McArthur, Grant A. ;

Ribas, Antoni ;

Eng, Susan ;

Hsu, Jessie J. ;

Rooney, Isabelle Anne ;

Larkin, James M. G. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[5] Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine [J].

Grob, J. -J. ;

Amonkar, M. M. ;

Martin-Algarra, S. ;

Demidov, L. V. ;

Goodman, V. ;

Grotzinger, K. ;

Haney, P. ;

Kaempgen, E. ;

Karaszewska, B. ;

Mauch, C. ;

Miller, W. H., Jr. ;

Millward, M. ;

Mirakhur, B. ;

Rutkowski, P. ;

Chiarion-Sileni, V. ;

Swann, S. ;

Hauschild, A. .

ANNALS OF ONCOLOGY, 2014, 25 (07) :1428-1436

[6] Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial [J].

Grob, Jean Jacques ;

Amonkar, Mayur M. ;

Karaszewska, Boguslawa ;

Schachter, Jacob ;

Dummer, Reinhard ;

Mackiewicz, Andrzej ;

Stroyakovskiy, Daniil ;

Drucis, Kamil ;

Grange, Florent ;

Chiarion-Sileni, Vanna ;

Rutkowski, Piotr ;

Lichinitser, Mikhail ;

Levchenko, Evgeny ;

Wolter, Pascal ;

Hauschild, Axel ;

Long, Georgina V. ;

Nathan, Paul ;

Ribas, Antoni ;

Flaherty, Keith ;

Sun, Peng ;

Legos, Jeffrey J. ;

McDowell, Diane Opatt ;

Mookerjee, Bijoyesh ;

Schadendorf, Dirk ;

Robert, Caroline .

LANCET ONCOLOGY, 2015, 16 (13) :1389-1398

[7] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma [J].

Larkin, James ;

Ascierto, Paolo A. ;

Dreno, Brigitte ;

Atkinson, Victoria ;

Liszkay, Gabriella ;

Maio, Michele ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Dutriaux, Caroline ;

Garbe, Claus ;

Sovak, Mika A. ;

Chang, Ilsung ;

Choong, Nicholas ;

Hack, Stephen P. ;

McArthur, Grant A. ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20) :1867-1876

[8] Interpreting the significance of changes in health-related quality-of-life scores [J].

Osoba, D ;

Rodrigues, G ;

Myles, J ;

Zee, B ;

Pater, J .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :139-144

[9] Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study [J].

Schadendorf, D. ;

Amonkar, M. M. ;

Milhem, M. ;

Grotzinger, K. ;

Demidov, L. V. ;

Rutkowski, P. ;

Garbe, C. ;

Dummer, R. ;

Hassel, J. C. ;

Wolter, P. ;

Mohr, P. ;

Trefzer, U. ;

Lefeuvre-Plesse, C. ;

Rutten, A. ;

Steven, N. ;

Ullenhag, G. ;

Sherman, L. ;

Wu, F. S. ;

Patel, K. ;

Casey, M. ;

Robert, C. .

ANNALS OF ONCOLOGY, 2014, 25 (03) :700-706

[10] Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma [J].

Schadendorf, Dirk ;

Amonkar, Mayur M. ;

Stroyakovskiy, Daniil ;

Levchenko, Evgeny ;

Gogas, Helen ;

de Braud, Filippo ;

Grob, Jean-Jacques ;

Bondarenko, Igor ;

Garbe, Claus ;

Lebbe, Celeste ;

Larkin, James ;

Chiarion-Sileni, Vanna ;

Millward, Michael ;

Arance, Ana ;

Mandala, Mario ;

Flaherty, Keith T. ;

Nathan, Paul ;

Ribas, Antoni ;

Robert, Caroline ;

Casey, Michelle ;

DeMarini, Douglas J. ;

Irani, Jhangir G. ;

Aktan, Gursel ;

Long, Georgina V. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (07) :833-840

← 1 2 →